The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm

Marcin Krawczyk, Monika Rau, Frank Grünhage, Jörn M. Schattenberg, Heike Bantel, Anita Pathil, Münevver Demir, Johannes Kluwe, Tobias Boettler, Andreas Geier, Frank Lammert, NAFLD Clinical Study Group (NAFLD CSG) – 8 February 2017

Early detection and curative treatment of hepatocellular carcinoma: A cost‐effectiveness analysis in France and in the United States

Benjamin Cadier, Julie Bulsei, Pierre Nahon, Olivier Seror, Alexis Laurent, Isabelle Rosa, Richard Layese, Charlotte Costentin, Carole Cagnot, Isabelle Durand‐Zaleski, Karine Chevreul, the ANRS CO12 CirVir and CHANGH groups – 8 February 2017 – Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence‐based monitoring. The objective of this study was to estimate the cost‐effectiveness of complying with HCC screening guidelines.

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry

Carlos Fernández Carrillo, Sabela Lens, Elba Llop, Juan Manuel Pascasio, Javier Crespo, Juan Arenas, Inmaculada Fernández, Carme Baliellas, José Antonio Carrión, Manuel de la Mata, Maria Buti, Lluís Castells, Agustín Albillos, Manuel Romero, Juan Turnes, Clara Pons, José María Moreno‐Planas, José Javier Moreno‐Palomares, Conrado Fernández‐Rodriguez, Javier García‐Samaniego, Martín Prieto, Miguel Fernández Bermejo, Javier Salmerón, Ester Badia, Magdalena Salcedo, José Ignacio Herrero, Rafael Granados, Michel Blé, Zoe Mariño, José Luis Calleja – 7 February 2017 – Direct‐acting antiviral agent

Caspase‐cleaved keratin‐18 fragments increase during alcohol withdrawal and predict liver‐related death in patients with alcoholic liver disease

Sebastian Mueller, Pierre Nahon, Vanessa Rausch, Tessa Peccerella, Ines Silva, Eray Yagmur, Beate K. Straub, Carolin Lackner, Helmut K. Seitz, Pierre Rufat, Angela Sutton, Heike Bantel, Thomas Longerich – 7 February 2017 – Noninvasive assessment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is still unsettled, but essential for the evaluation of disease progression.

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10‐year intention‐to‐treat analysis

Min Woo Lee, Steven S. Raman, Nazanin H. Asvadi, Surachate Siripongsakun, Robert M. Hicks, Jeffrey Chen, Akeanong Worakitsitisatorn, Justin McWilliams, Myron J. Tong, Richard S. Finn, Vatche G. Agopian, Ronald W. Busuttil, David S.K. Lu – 7 February 2017 – In a long‐term (10‐year) study of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) as bridging therapy in patients listed for orthotopic liver transplantation (LT), we evaluated the impact of RFA on waiting list dropout rate, post‐LT tumor recurrence, and long‐term intention‐to‐treat, disease‐specific survival (DSS).

Subscribe to